Fatty liver disease

Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…

A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.

A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…